Overall, zongertinib represents a first-in-class, HER2-selective oral TKI, that delivers compelling response rates and a favorable tolerability profile in a difficult-to-treat NSCLC population (Brazel et al., 2025[18]). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.